It has been illustrated that inhibiting BMP signaling diminished the expression of astrocytic SMAD1 and induced early oligodendrogenesis-mediated remyelination, implying a therapeutic potential in MS [52]. The gene discussed is SMAD1; the disease is myeloid sarcoma.